Back to Journals » Journal of Pain Research » Volume 11

Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis

Authors Meng F, Peng K, Yang JP, Ji FH, Xia F, Meng XW

Received 22 March 2018

Accepted for publication 24 July 2018

Published 12 October 2018 Volume 2018:11 Pages 2343—2351

DOI https://doi.org/10.2147/JPR.S168650

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Katherine Hanlon


Fan Meng, Ke Peng, Jian-Ping Yang, Fu-Hai Ji, Fan Xia, Xiao-Wen Meng

Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Aim: This meta-analysis was performed to evaluate the efficacy and safety of botulinum toxin-A (BTX-A) for the treatment of neuralgia.
Methods: We searched PubMed, EMBASE, and Cochrane databases to identify randomized controlled trials (RCTs) comparing BTX-A treatment with saline for alleviating neuropathic pain. Primary outcome measures were pain scores up to 24 weeks after treatment. Secondary outcomes were hours of sleep, Short Form-36 (SF-36) life quality questionnaire, and adverse events. We used Review Manager 5.3 for the data analyses.
Results: Twelve RCTs were included (n=495). Pain scores in the BTX-A group were significantly lower compared to the saline group at 4 weeks (mean difference [MD] =–1.64, 95% CI [–3.21, –0.07], P=0.04), 12 weeks (MD =–1.49, 95% CI [−2.05, –0.93], P<0.00001), and 24 weeks (MD =–1.61, 95% CI [−2.81, –0.40], P=0.009). There were no significant differences in hours of sleep, SF-36 questionnaire, or the incidence of injection pain or hematoma between the two groups. No serious adverse events associated with BTX-A were noted. Fourteen out of 108 patients (12.9%) with trigeminal neuralgia experienced mild facial asymmetry after the BTX-A treatment.
Conclusion: Based on the current evidence, BTX-A may be an effective and safe option for the treatment of neuralgia. Due to the limited number of patients included in this meta-analysis, more trials are still needed to confirm these results.

Keywords: botulinum toxin, neuralgia, neuropathic pain, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]